Chemoimmunotherapy of cancer: cyclophosphamide-resistant tumour cells are equally sensitive as the original tumour cell population to local IL-2 immunotherapy.
Chemotherapy and IL-2-mediated biotherapy represent two modalities of cancer treatment; combination of the two modalities could theoretically help to increase the efficacy of the treatment and decrease the doses as well as toxicity of both components if it could be shown that the chemotherapy-resistant tumour cells selected by treatment with cytostatics are not less sensitive to IL-2-mediated biotherapy than the original chemotherapy-sensitive tumour cell population. In this report we have tried to investigate whether the population of tumour cells selected by chemotherapy and resistant to a chemotherapeutic agent is more, equally, or less sensitive to IL-2 treatment than the parental tumour cell population. For these purposes, we have used a pair of homologous tumour cell lines differing in sensitivity to cyclophosphamide. It could be shown that both tumour cell lines, the CY-sensitive (MC 14) and CY-resistant (MC 14/8R) line were equally sensitive to local IL-2 immunotherapy. Similarly, comparison of the cyclophosphamide-sensitive and cyclophosphamide-resistant tumour target cells to LAK cell-mediated cytolysis in vitro revealed that both tumour cell populations were equally sensitive to the LAK cell effect.
Símová
J
J
Institute of Molecular Genetics, Czechoslovak Academy of Sciences, Praha.
Bubeník
J
J
Jandlová
T
T
D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D004351:Drug Resistance; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D003520:Cyclophosphamide